Havrix Injection, Suspension
NDC Package 58160-825-52
Package Information
Havrix (hepatitis a vaccine) injection is hAVRIX is indicated for active immunization against disease caused by hepatitis A virus (HAV). This formulation utilizes a injection, suspension delivery system. Marketed by Glaxosmithkline Biologicals Sa, this product is identified by NDC 58160-825 and is authorized under FDA application BLA103475.
Identification & Billing
- RxCUI: 798477 - hepatitis A vaccine adult (HepA) 1440 UNT in 1 ML Prefilled Syringe
- RxCUI: 798477 - 1 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Prefilled Syringe
- RxCUI: 798477 - hepatitis A vaccine (inactivated) strain HM175 1440 UNT per 1 ML Prefilled Syringe
- RxCUI: 798479 - HAVRIX adult vaccine 1440 UNT in 1 ML Prefilled Syringe
- RxCUI: 798479 - 1 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Prefilled Syringe [Havrix]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 58160 - Glaxosmithkline Biologicals Sa
- 58160-825 - Havrix
- 58160-825-52 - 10 SYRINGE in 1 CARTON / .5 mL in 1 SYRINGE (58160-825-43)
- 58160-825 - Havrix
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 58160-825-52 identifies a specific commercial package of 10 syringe in 1 carton / .5 ml in 1 syringe (58160-825-43) of Havrix, a vaccine label labeled by Glaxosmithkline Biologicals Sa. This product is billed per "ML" milliliter and contains an estimated amount of 5 billable units per package. This injection, suspension is formulated for intramuscular use and contains hepatitis a virus strain hm175 antigen (formaldehyde inactivated) as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glaxosmithkline Biologicals Sa on February 16, 2007. The current certification is valid through December 31, 2027.
How is this Glaxosmithkline Biologicals Sa product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 58160082552. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 5 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.